Compare EXPI & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXPI | AGIO |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2010 | 2013 |
| Metric | EXPI | AGIO |
|---|---|---|
| Price | $6.90 | $29.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $11.50 | ★ $36.63 |
| AVG Volume (30 Days) | ★ 998.8K | 761.1K |
| Earning Date | 05-27-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,147,681.00 | $43,011,000.00 |
| Revenue This Year | $6.93 | $103.08 |
| Revenue Next Year | $7.02 | $126.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 220.39 | N/A |
| 52 Week Low | $6.91 | $22.24 |
| 52 Week High | $12.23 | $46.00 |
| Indicator | EXPI | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 21.52 | 53.62 |
| Support Level | N/A | $26.40 |
| Resistance Level | $11.36 | $29.49 |
| Average True Range (ATR) | 0.34 | 1.24 |
| MACD | -0.03 | 0.21 |
| Stochastic Oscillator | 8.66 | 64.33 |
eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services. The company mainly operates in the United States and Canada, and it also has operations in the United Kingdom, Australia, South Africa, France, India, Portugal, and Mexico, among others.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.